The Deadly World of Fake Drugs

Resident Fellow
Roger Bate

Suresh Sati, a large and cheerful man from a small city in northeastern India, has been hunting down counterfeit goods for more than half his 49 years. From the moment I meet him at my hotel in Delhi, I can tell that he enjoys his work. Most days, Sati makes the rounds visiting his undercover agents, who live near the main wholesale markets in Delhi, where most fakes are traded. They pass on news and rumors about new dealers and crooked police. As we set off down the road toward one of the city's sprawling markets, Sati smiles nostalgically as he recalls his first anticounterfeit raid, back in 1981, on a small-scale outfit manufacturing knockoff tv antennas. His work has changed a great deal since then; his targets today are far better financed, organized, and dangerous. These days, Sati runs a company called "The Protector," which leads raids for multinational corporate clients. His bread-and-butter work: hunting for fake drugs.

Back in his basement office the next day, in an unremarkable building in residential Delhi, Sati offers me a glimpse of what he is up against. He lays out the samples of phony drugs he has collected from recent clandestine purchases and the previous week's raid. He places two vials of liquid erythromycin, an antibiotic used to treat bacterial infections, on the table in front of me. One vial is the real thing; the other contains water from a Delhi tap. "Which one is the fake?" Sati quizzes. I can't say. They look absolutely identical.

During the past decade, trafficking in counterfeit drugs has become one of the world's fastest-growing criminal enterprises. The World Health Organization (WHO) estimates that more than 30 percent of medicines on sale in parts of Africa, Asia, and Latin America are fakes. By 2010, the global turnover for phony pharmaceuticals is projected to be $75 billion, a 90 percent increase since 2005. A sharp increase in drug seizures also points to a mounting crisis. In 2006, the European Commission reported that customs agents intercepted 2.7 million counterfeit drugs at EU borders--an increase of 384 percent from a year earlier. . . .

Download file Click here to view the full text of this article as an Adobe Acrobat PDF.

Roger Bate is a resident fellow at AEI.

Reproduced with permission from FOREIGN POLICY, www.ForeignPolicy.com, #168, September/October 2008. Copyright 2008 by Washingtonpost.Newsweek Interactive, LLC (WPNI), a subsidiary of The Washington Post Company.

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Roger
Bate
  • Roger Bate is an economist who researches international health policy, with a particular focus on tropical disease and substandard and counterfeit medicines. He also writes on general development policy in Asia and Africa. He writes regularly for AEI's Health Policy Outlook.
  • Phone: 202-828-6029
    Email: rbate@aei.org
  • Assistant Info

    Name: Katherine Earle
    Phone: (202) 862-5872
    Email: katherine.earle@aei.org

What's new on AEI

image How to beat Memorial Day traffic forever
image Bernanke stumbles, markets react
image Don't edit the First Amendment
image Home Economics
AEI on Facebook
Events Calendar
  • 27
    MON
  • 28
    TUE
  • 29
    WED
  • 30
    THU
  • 31
    FRI
Wednesday, May 29, 2013 | 4:30 p.m. – 6:00 p.m.
Solar radiation management: An evolving climate policy option

As the controversy over climate policy has grown, it has been said that greenhouse gas (GHG) control is too hard but solar radiation management (SRM) is too easy. Join AEI for a discussion of the potential economic benefits, as well as the risks of SRM with Lee Lane, J. Eric Bickel and Nobel Laureate Thomas Schelling. A reception will follow.

Thursday, May 30, 2013 | 12:00 p.m. – 2:15 p.m.
Public employee pensions: How large are the deficits? What changes can be made?

At this event, panelists will address pension reform challenges by presenting the results of three research papers commissioned by AEI through a generous grant from the Smith Richardson Foundation.

Friday, May 31, 2013 | 9:15 a.m. – 11:15 a.m.
Long-term care: Markets or mandates?

Mark Warshawsky, a well-known expert in retirement finance and a newly appointed commissioner, will explain the implications of a publicly funded long-term care insurance program. Then a panel will debate whether another government program the best way to ensure that families can afford to provide the necessary services for their aging loved ones.

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled today.
No events scheduled this day.